Your August Cardiometabolic Round-Up

View in browser

The Monthly Beat: BP Drug Recall, New Diabetic Kidney Treatment & More

AUGUST

Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors

The Lancet

A large, international, observational study found that initiation of SGLT2 inhibitors versus DPP-4 inhibitors was associated with lower risks of heart failure, death, myocardial infarction, and stroke, providing further support for the cardiovascular benefits associated with use of SGLT2 inhibitors in patients with type 2 diabetes.

Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial

The Lancet Neurology

An exploratory primary cognitive outcome from REWIND study indicated that long-term treatment with dulaglutide may reduce cognitive impairment in people with type 2 diabetes.

Exposure to DPP ‐4 inhibitors and risk of pneumonia among people with type 2 diabetes

Diabetes, Obesity and Metabolism

The findings of a retrospective cohort study and meta‐analysis exhibited that use of DPP‐4i can be considered safe with regards to the risk of pneumonia.

Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec

Diabetes Care

Results from the ONSET9 study revealed that in combination with insulin degludec, faster aspart provided effective overall glycemic control, superior PPG control, and a lower rate of severe or BG-confirmed hypoglycemia versus IAsp in adults with type 2 diabetes not optimally controlled with a basal-bolus regimen.

Atherosclerotic Risk and Statin Use Among Patients With Peripheral Artery Disease

Journal of the American College of Cardiology

A retrospective cohort study of adults among 943,232 patients found that despite having high risk for ASCVD events, patients with PAD were less likely to be taking a statin versus those with CHD or cerebrovascular disease. Therefore, ASCVD risk-reduction interventions including statin therapy in patients with PAD are warranted.

Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women

JAMA Network

Principal Results from the Women's Health Initiative Randomized Controlled Trial indicated that woman’s menopause status is important to consider while assessing their CV risk.

READ BLOG